Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunex/Ivax Paclitaxel ANDA Is First To File; Hauser Will Supply Bulk Drug

Executive Summary

FDA has confirmed that the Immunex/Ivax paclitaxel ANDA was the first to be filed, Ivax announced Aug. 13. The decision will give the companies 180 days of marketing exclusivity upon approval of the ANDA.

You may also be interested in...



Bristol To Focus On Paraplatin For Oncology Growth; UFT Review Delayed

Bristol-Myers Squibb is looking to Paraplatin (carboplatin) to lead oncology growth in the wake of a court decision opening the door to generic competition for its Taxol (paclitaxel) franchise.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel